» Articles » PMID: 35455968

Anti-β2-GPI Antibodies Induce Endothelial Cell Expression of Tissue Factor by LRP6 Signal Transduction Pathway Involving Lipid Rafts

Abstract

In this study we analyzed whether anti-β2-GPI antibodies from patients with APS induce the endothelial cell expression of Tissue Factor (TF) by a LRP6 signal transduction pathway involving lipid rafts. HUVEC were stimulated with affinity purified anti-β2-GPI antibodies. Both LRP6 and β-catenin phosphorylation, as well as TF expression, were evaluated by western blot. Results demonstrated that triggering with affinity purified anti-β2-GPI antibodies induced LRP6 phosphorylation with consequent β-catenin activation, leading to TF expression on the cell surface. Interestingly, the lipid rafts affecting agent methyl-β-cyclodextrin as well as the LRP6 inhibitor Dickkopf 1 (DKK1) partially reduced the anti-β2-GPI antibodies effect, indicating that the anti-β2-GPI effects on TF expression may depend on a signalling transduction pathway involving both lipid rafts and LRP6. An interaction between β2-GPI, LRP6 and PAR-2 within these microdomains was demonstrated by gradient fractionation and coimmunoprecipitation experiments. Thus, anti-β2-GPI antibodies react with their target antigen likely associated to LRP6 and PAR-2 within plasma membrane lipid rafts of the endothelial cell. Anti-β2-GPI binding triggers β-catenin phosphorylation, leading to a procoagulant phenotype characterized by TF expression. These findings deal with a novel signal transduction pathway which provides new insight in the APS pathogenesis, improving the knowledge of valuable therapeutic target(s).

Citing Articles

Wnt signaling as a translational target in rheumatoid and psoriatic arthritis.

Riitano G, Spinelli F, Manganelli V, Caissutti D, Capozzi A, Garufi C J Transl Med. 2025; 23(1):158.

PMID: 39905450 PMC: 11796213. DOI: 10.1186/s12967-025-06174-2.


Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities.

Askarizadeh F, Karav S, Jamialahmadi T, Sahebkar A Pharmacol Rep. 2024; 77(1):43-71.

PMID: 39680334 DOI: 10.1007/s43440-024-00678-2.


Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome.

Feng W, Qiao J, Tan Y, Liu Q, Wang Q, Yang B Front Immunol. 2024; 15:1361519.

PMID: 39044818 PMC: 11263079. DOI: 10.3389/fimmu.2024.1361519.


Role of Lipid Rafts on LRP8 Signaling Triggered by Anti-β2-GPI Antibodies in Endothelial Cells.

Riitano G, Capozzi A, Recalchi S, Augusto M, Conti F, Misasi R Biomedicines. 2023; 11(12).

PMID: 38137358 PMC: 10740635. DOI: 10.3390/biomedicines11123135.


Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.

Garofalo M, Bonanno S, Marcuzzo S, Pandini C, Scarian E, Dragoni F Biol Direct. 2023; 18(1):57.

PMID: 37705059 PMC: 10498611. DOI: 10.1186/s13062-023-00413-6.


References
1.
Semenov M, Tamai K, He X . SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280(29):26770-5. DOI: 10.1074/jbc.M504308200. View

2.
He X, Semenov M, Tamai K, Zeng X . LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development. 2004; 131(8):1663-77. DOI: 10.1242/dev.01117. View

3.
Radic M, Pattanaik D . Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome. Front Immunol. 2018; 9:969. PMC: 5949565. DOI: 10.3389/fimmu.2018.00969. View

4.
Lopez-Pedrera C, Aguirre M, Buendia P, Barbarroja N, Ruiz-Limon P, Collantes-Estevez E . Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum. 2010; 62(3):869-77. DOI: 10.1002/art.27299. View

5.
Sorice M, Longo A, Capozzi A, Garofalo T, Misasi R, Alessandri C . Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007; 56(8):2687-97. DOI: 10.1002/art.22802. View